Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 23Neutropenia 22Neoplasms 7Chemotherapy-induced Neutropenia 7Lymphoma, Non-Hodgkin 6Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Lymphoma 3Fever 3Febrile Neutropenia 3Colorectal Neoplasms 3Rectal Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Previously Treated Non Small Cell Lung Cancer 1Neuroectodermal Tumors, Primitive, Peripheral 1Malignant Solid Tumors 1Lymphoma, T-Cell, Peripheral 1Leukemia, Myeloid, Acute 1

Interventions

10-propargyl-10-deazaaminopterin 12Cyclophosphamide 8Prednisone 7belinostat 6Vincristine 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Doxorubicin 6Brentuximab Vedotin 5romidepsin 4mogamulizumab 4darinaparsin 4Vitamin B 12 4Gemcitabine 4Folic Acid 4selinexor 3denileukin diftitox 3Nivolumab 3Injections 3Bendamustine Hydrochloride 3tislelizumab 2tipifarnib 2tenalisib 2duvelisib 2Rituximab 2Lenalidomide 2HBI-8000 2Fenretinide 2E7777 fusion protein 2AFM13 2venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, T-Cell, Peripheral × pegfilgrastim × Clear all
NCT00211185 2020-03-18

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Eisai Inc.

Phase 2 Completed
49 enrolled 11 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡